AbCellera Biologics Inc.

XNASHealth care

Last traded price · USD

$12.28

+0.02%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:55 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $12.28
Volume: 12,604
Day's high: —
Day's low: —

In brief

AbCellera Biologics Inc. is a health care company listed on Nasdaq, valued at about $3.98B.
Its shares closed at $12.28 on 4 Nov 2026, up 152.2% over the past year.
From India you can buy ABCL in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy AbCellera Biologics Inc. (ABCL) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ABCL share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ABCL options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −6.6% (SPY −1.6%, XLV +13.5%). 3 months: +107.4% (SPY −0.4%, XLV +15.5%). 1 year: +152.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ABCL, SPY and XLV · as of 4 Nov 2026
5.6 days to cover short interest
30.9M shares were sold short at the 15 Oct 2026 settlement, 10.1% of the 306.6M shares outstanding; covering them would take 5.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $12.28 was 0.2% below its 50-day average ($12.31) and 76.3% above its 200-day average ($6.97). It has closed above the 200-day for 117 sessions, since 20 May 2026. The 50-day average crossed above the 200-day on 1 Jun 2026, 109 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
78% of the way up its 52-week range
Closed at $12.28 on 4 Nov 2026: 18.2% below the 52-week high of $15.02 (30 Sep 2026) and 347.4% above the low of $2.75 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−6.6%

6 months+143.7%

1 year+152.2%

5 years−29.3%

Newswire

About

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Website

Notable moves

August 10, 2026
+34.78%
June 10, 2025
+20.32%
August 10, 2022
+20.07%

Newswire

About

Website

Notable moves

August 10, 2026
+34.78%
June 10, 2025
+20.32%
August 10, 2022
+20.07%

AbCellera Biologics Inc.

XNASHealth care

Last traded price · USD

$12.28

+0.02%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:55 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $12.28
Volume: 12,604
Day's high: —
Day's low: —

In brief

AbCellera Biologics Inc. is a health care company listed on Nasdaq, valued at about $3.98B.
Its shares closed at $12.28 on 4 Nov 2026, up 152.2% over the past year.
From India you can buy ABCL in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy AbCellera Biologics Inc. (ABCL) shares from India?

Do I need the price of a whole ABCL share to invest?

How much can I invest in US stocks in a year?

Can I trade ABCL options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −6.6% (SPY −1.6%, XLV +13.5%). 3 months: +107.4% (SPY −0.4%, XLV +15.5%). 1 year: +152.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ABCL, SPY and XLV · as of 4 Nov 2026
5.6 days to cover short interest
30.9M shares were sold short at the 15 Oct 2026 settlement, 10.1% of the 306.6M shares outstanding; covering them would take 5.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $12.28 was 0.2% below its 50-day average ($12.31) and 76.3% above its 200-day average ($6.97). It has closed above the 200-day for 117 sessions, since 20 May 2026. The 50-day average crossed above the 200-day on 1 Jun 2026, 109 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
78% of the way up its 52-week range
Closed at $12.28 on 4 Nov 2026: 18.2% below the 52-week high of $15.02 (30 Sep 2026) and 347.4% above the low of $2.75 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−6.6%

6 months+143.7%

1 year+152.2%

5 years−29.3%

Newswire

About

Website

Notable moves

August 10, 2026
+34.78%
June 10, 2025
+20.32%
August 10, 2022
+20.07%

Newswire

About

Website

Notable moves

August 10, 2026
+34.78%
June 10, 2025
+20.32%
August 10, 2022
+20.07%

AbCellera Biologics Inc.

AbCellera Biologics Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

5.6 days to cover short interest

Below its 50-day average, above its 200-day

78% of the way up its 52-week range

AbCellera Biologics Inc.

AbCellera Biologics Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

5.6 days to cover short interest

Below its 50-day average, above its 200-day

78% of the way up its 52-week range